Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joost S Vermaat

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Neoplasia (New York, N.Y.)|January 15, 2010
Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patientsJeanine M Roodhart, Marlies H Langenberg, Joost S Vermaat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2011
Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatmentJoost S Vermaat, Isaac J Nijman, Marco J Koudijs, et al.
European Journal of Cancer (Oxford, England : 1990)|August 17, 2010
Expression of nuclear FIH independently predicts overall survival of clear cell renal cell carcinoma patientsStephanie G C Kroeze, Joost S Vermaat, Aram van Brussel, et al.
The Journal of Clinical Investigation|July 13, 2011
Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistanceRon C J Schackmann, Miranda van Amersfoort, Judith H I Haarhuis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancerJeany M Rademaker-Lakhai, Laurens V Beerepoot, Niven Mehra, et al.
Genome Biology|October 22, 2011
Chromothripsis is a common mechanism driving genomic rearrangements in primary and metastatic colorectal cancerWigard P Kloosterman, Marlous Hoogstraat, Oscar Paling, et al.
European Urology|January 31, 2012
Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patientsJoost S Vermaat, Frank L Gerritse, Astrid A van der Veldt, et al.
The Journal of Pathology|June 8, 2013
Regulation of E2F1 by the von Hippel-Lindau tumour suppressor protein predicts survival in renal cell cancer patientsDorus A Mans, Joost S Vermaat, Bart G Weijts, et al.
Haematologica|May 25, 2019
<i>MYD88</i> mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosisJoost S Vermaat, Sebastiaan F Somers, Liesbeth C de Wreede, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Neoplasia (New York, N.Y.)|January 15, 2010
Late release of circulating endothelial cells and endothelial progenitor cells after chemotherapy predicts response and survival in cancer patientsJeanine M Roodhart, Marlies H Langenberg, Joost S Vermaat, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2011
Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatmentJoost S Vermaat, Isaac J Nijman, Marco J Koudijs, et al.
European Journal of Cancer (Oxford, England : 1990)|August 17, 2010
Expression of nuclear FIH independently predicts overall survival of clear cell renal cell carcinoma patientsStephanie G C Kroeze, Joost S Vermaat, Aram van Brussel, et al.
The Journal of Clinical Investigation|July 13, 2011
Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistanceRon C J Schackmann, Miranda van Amersfoort, Judith H I Haarhuis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2007
Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancerJeany M Rademaker-Lakhai, Laurens V Beerepoot, Niven Mehra, et al.
Genome Biology|October 22, 2011
Chromothripsis is a common mechanism driving genomic rearrangements in primary and metastatic colorectal cancerWigard P Kloosterman, Marlous Hoogstraat, Oscar Paling, et al.
European Urology|January 31, 2012
Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patientsJoost S Vermaat, Frank L Gerritse, Astrid A van der Veldt, et al.
The Journal of Pathology|June 8, 2013
Regulation of E2F1 by the von Hippel-Lindau tumour suppressor protein predicts survival in renal cell cancer patientsDorus A Mans, Joost S Vermaat, Bart G Weijts, et al.
Haematologica|May 25, 2019
<i>MYD88</i> mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosisJoost S Vermaat, Sebastiaan F Somers, Liesbeth C de Wreede, et al.
Pageof 1